Via Nova Therapeutics Inc
Zapisane w:
| Wydane w: | GlobalData Deals and Alliances Profiles (2025) |
|---|---|
| Wydane: |
GlobalData plc
|
| Hasła przedmiotowe: | |
| Dostęp online: | Citation/Abstract Full Text - PDF |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
| Streszczenie: | Via Nova Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile Via Nova Therapeutics Inc (Via Nova) is a biotechnology company that develops therapies for the treatment of viral diseases. The company's lead product candidate, VNT-101, is a small molecule to treat influenza A infection. Its lead products have demonstrated activity in vitro against seasonal influenza A and highly pathogenic avian influenza (HPAI) H5N1 and H7N9 strains. Via Nova Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. |
|---|---|
| Źródło: | ABI/INFORM Trade & Industry |